PACE-LUNG

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Mar 16, 2022 → Oct 28, 2026

Cited window

May 29, 2023 → Oct 28, 2026

Retrieved

Oct 28, 2026

Title

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Registry

NCT05281406

Study IDs

PACE LUNG

Sponsor

Goethe University

Design

Phase 2 · Interventional, single group

Status

Recruiting

Enrollment

50 estimated

Start

2021-11-12 actual

Primary completion

2025-11 estimated

Primary endpoint

Progression Free Survival (PFS1)

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –45 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative survey of HCPs. Repeated posts and relays of the same discussion cannot be counted as independent agreement.
• –No full protocol or exact-trial results publication was available. Registry statements describe methods and hypotheses; reported outcomes come from commentary about presentations.
• –Discussions that do not name PACE-LUNG, or use different spellings, may be absent. Some relevant passages were not fully assessed, so the report is not a complete account of public discussion.
• –The podcast and preview speech cannot be assigned to named individuals. The podcast does not establish that its personal treatment accounts are HCP recommendations.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Reported PFS and OS estimates have different or incompletely specified time origins. Historical comparisons and presentation relays cannot establish comparative treatment benefit.
• –Baseline-undetectable patients and patients achieving clearance after starting treatment are different groups; favorable prognosis does not by itself establish that chemotherapy can safely be omitted.
• –Personal accounts do not provide aggregate adverse-event, comparative safety or trial quality-of-life results. The hyperthermia rationale is not demonstrated clinical benefit.

How reports are built and checked: Methods.

Last checked for new commentary Oct 28, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "PACE-LUNG" (NCT05281406), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "pace-lung-05281406". If you cannot make requests, read https://www.erudio.com/reports/pace-lung-nct05281406.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05281406", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05281406 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/pace-lung-nct05281406.json
curl https://www.erudio.com/reports/pace-lung-nct05281406.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "pace-lung-05281406" })